öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºËÕ±¾Àû
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º141

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚ¶þÁÙ´²Ñ§Ôº
Ö°³Æ£º
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ·ÖÃÚÓë´úл¼²²¡¡¢È«¿Æҽʦ
Ñо¿ÁìÓò£º ÄÚ·ÖÃÚÓë´úлÐÔ¼²²¡£¬ÖصãÑо¿ÌÇÄò²¡ÏµÍ³ÉúÎïѧ·¢²¡»úÖƼ°¸ÉÔ¤ÊÖ¶Î
Ñо¿ÁìÓò£º ÄÚ·ÖÃÚÓë´úлÐÔ¼²²¡£¬ÖصãÑо¿ÌÇÄò²¡ÏµÍ³ÉúÎïѧ·¢²¡»úÖƼ°¸ÉÔ¤ÊֶΠ[ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**£¬**-5260


¸öÈ˼òÊö :
1964-7³öÉú£¬´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚ¶þÒ½ÔºÄÚ·ÖÃÚѧ¿ÆÖ÷ÈΣ¬ÄÚ·ÖÃÚ1¿ÆÖ÷ÈΣ¬Èý¼¶½ÌÊÚ£¬Ôø»ñÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½¶þ¡¢ÈýµÈ½±¸÷1Ïî¡£1981.9-1986.8 ɽ¶«Ò½¿Æ´óѧҽѧϵ£¬Ñ§Ê¿1986.9-1989.8 ±±¾©Ð­ºÍÒ½¿Æ´óѧ£¬Ò½Ñ§¼ìÑéÓëÕï¶Ï£¬Ë¶Ê¿2001.9-2004.8 ´óÁ¬Ò½¿Æ´óѧ£¬²¡ÀýÓ벡ÀíÉúÀíѧ£¬²©Ê¿ÖлªÒ½Ñ§»áÌÇÄò²¡Ñ§·Ö»áµÚËÄ¡¢Îå¡¢Áù½ìίԱÖйúҽʦЭ»áÄÚ·ÖÃÚÓë´úлÐÔҽʦЭ»á³£Î¯ÖлªÔ¤·Àҽѧ»áÌÇÄò²¡·ÀÖÎÓë¿ØÖÆίԱίԱÁÉÄþʡҽѧ»áÄÚ·ÖÃÚѧ»á¸±Ö÷ÈÎίԱ´óÁ¬Ò½Ñ§»áÄÚ·ÖÃÚöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱÖ÷ÈÎίԱÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾¡¢ÖлªÌÇÄò²¡ÔÓÖ¾¡¢ÖйúÌÇÄò²¡ÔÓÖ¾¡¢Ò½Ñ§ÓëÕÜѧÔÓÖ¾±àί

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿£ºÕæʵÊÀ½çÌÇÄò²¡¹ÜÀí£¨ÖйúҽʦЭ»á£©£¬10Íò
·¢±íÂÛÎÄ£º
1. 1£®Li M, Zhou H, Guan Y, Peng H, Wang S, Zhang P, Su B£¨Í¨Ñ¶£©. Positive hepatitis B surface antibody is associated with reduced risk of diabetes mellitus in retired female Chinese workers. J Diabetes. 2016 Jan8(1):158-61. doi: 10.1111/1753-0407.12317.2. Zhou X, Ji L, Ran X, Su B, Ji Q, Pan C, Weng J, Ma C, Hao C, Zhang D, Hu D CCMR Advisory Board and CCMR-3B Study Investigators. Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study. PLoS One. 2016 Jan 411(1):e**. doi: 10.1371/journal.pone.**.3. Huo X, Gao L, Guo L, Xu W, Wang W, Zhi X, Li L, Ren Y, Qi X, Sun Z, Li W, Ji Q, Ran X, Su B, Hao C, Lu J, Guo X, Zhuo H, Zhang D, Pan C, Weng J, Hu D, Yang X, Ji L. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016 Feb4(2):115-24. doi: 10.1016/S2213-8587(15)00508-24. Ji L, Ji L, Guo X, Ji Q, Gu W, Zhi X, Li X, Kuang H, Su B, Yan J, Yang X. Prevalence of microvascular diseases among tertiary care Chinese with early versus late onset of type 2 diabetes. J Diabetes Complications. 2015 Jan-Feb29(1):32-7. doi: 10.1016/j.jdiacomp.2014.08.010.5. Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, Mu Y, Hao C, Ji Q, Ran X, Su B, Zhuo H, Fox KA, Weber M, Zhang D CCMR Advisory Board CCMR-3B STUDY Investigators. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013 Oct126(10):925.e11-22. doi: 10.1016 /j.amjmed. 2013.02.035.6. Su B, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P, Meng X. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2015 Sep7(5):729-39. doi: 10.1111/1753-0407.12232.